The complex relationship between the gut microbiota and brain function has opened new frontiers in neuroscience. At the core of this emerging discipline, neurobiome researchers explore how the trillions of microbes living in the digestive system communicate with the brain through the gut-brain axis. Their studies investigate how changes in the microbiome can influence neurological disorders such as anxiety, depression, autism spectrum disorders, and neurodegenerative diseases like Parkinson’s and Alzheimer’s. Using cutting-edge techniques including genetic sequencing, metabolomics, and neuroimaging, these researchers seek to uncover the mechanisms by which gut bacteria affect brain chemistry, immune responses, and neural signaling.
The work of neurobiome researchers is rapidly reshaping how medicine understands brain health, emphasizing the importance of microbial ecosystems in neurological function. By collaborating with neurologists, immunologists, and dietitians, they aim to develop novel therapies such as probiotic treatments, dietary modifications, and microbial transplants to restore balance and improve cognitive and emotional outcomes. This interdisciplinary approach holds promise for more personalized and effective treatments, moving beyond symptom management to address underlying biological causes. As evidence mounts linking gut health to mental and neurological well-being, the contributions of neurobiome researchers will continue to expand, offering hope for innovative interventions in the future of neurology.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States